Wedbush Securities Inc. purchased a new stake in Dynavax Technologies Co. (NASDAQ:DVAX) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 10,500 shares of the biopharmaceutical company’s stock, valued at approximately $42,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Federated Investors Inc. PA lifted its stake in shares of Dynavax Technologies by 4.1% in the 1st quarter. Federated Investors Inc. PA now owns 3,813,400 shares of the biopharmaceutical company’s stock valued at $27,876,000 after acquiring an additional 151,800 shares during the last quarter. Chicago Capital LLC raised its position in Dynavax Technologies by 15.5% during the 2nd quarter. Chicago Capital LLC now owns 2,937,266 shares of the biopharmaceutical company’s stock worth $11,720,000 after purchasing an additional 393,124 shares during the last quarter. Eagle Asset Management Inc. raised its position in Dynavax Technologies by 4.0% during the 1st quarter. Eagle Asset Management Inc. now owns 2,435,710 shares of the biopharmaceutical company’s stock worth $17,805,000 after purchasing an additional 94,186 shares during the last quarter. Rhenman & Partners Asset Management AB raised its position in Dynavax Technologies by 333.1% during the 2nd quarter. Rhenman & Partners Asset Management AB now owns 1,234,335 shares of the biopharmaceutical company’s stock worth $4,925,000 after purchasing an additional 949,335 shares during the last quarter. Finally, Clearbridge Investments LLC raised its position in Dynavax Technologies by 3.4% during the 1st quarter. Clearbridge Investments LLC now owns 1,161,338 shares of the biopharmaceutical company’s stock worth $8,489,000 after purchasing an additional 38,400 shares during the last quarter. Institutional investors own 82.41% of the company’s stock.

DVAX stock opened at $4.46 on Wednesday. The stock has a 50-day moving average price of $3.50 and a 200-day moving average price of $6.23. Dynavax Technologies Co. has a 1-year low of $2.60 and a 1-year high of $14.35. The company has a current ratio of 4.30, a quick ratio of 3.47 and a debt-to-equity ratio of 19.95. The firm has a market cap of $284.71 million, a PE ratio of -1.75 and a beta of 0.63.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by ($0.03). Dynavax Technologies had a negative return on equity of 304.71% and a negative net margin of 781.10%. The business had revenue of $8.30 million during the quarter, compared to the consensus estimate of $8.24 million. During the same period last year, the business posted ($0.63) earnings per share. The business’s revenue was up 564.0% on a year-over-year basis. On average, analysts forecast that Dynavax Technologies Co. will post -1.99 earnings per share for the current year.

Several research analysts recently issued reports on the company. BidaskClub raised Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, June 29th. Cantor Fitzgerald raised Dynavax Technologies from a “neutral” rating to an “overweight” rating and set a $20.00 target price for the company in a research report on Wednesday, July 10th. Cowen reaffirmed a “buy” rating on shares of Dynavax Technologies in a research report on Monday, June 3rd. ValuEngine raised Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Royal Bank of Canada lowered their target price on Dynavax Technologies to $13.00 and set an “outperform” rating for the company in a research report on Friday, May 24th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $16.88.

In other Dynavax Technologies news, Director Francis Cano acquired 16,667 shares of the stock in a transaction dated Monday, August 12th. The stock was purchased at an average cost of $3.00 per share, with a total value of $50,001.00. Following the transaction, the director now owns 118,484 shares in the company, valued at approximately $355,452. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, SVP Robert Coffman sold 32,218 shares of Dynavax Technologies stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $4.58, for a total value of $147,558.44. Following the completion of the transaction, the senior vice president now directly owns 132,470 shares of the company’s stock, valued at $606,712.60. The disclosure for this sale can be found here. Company insiders own 4.90% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Featured Article: Outstanding Shares and The Effect on Share Price

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.